Last updated 2026-08-24
- Raised $21.7M Seed round led by Add Ventures, Nov 2025
Total raised
$21.7M
Stage
—
Founded
2021
Headcount
27
HQ
Oxford, United Kingdom
Sector
Biotechnology
About
NeoVac is a clinical-stage pharmaceutical company developing next-generation lipid nanoparticle (LNP) technologies for mRNA vaccines and therapeutics. The company's proprietary platform aims to improve the delivery of RNA vaccines and treatments, offering enhanced safety, adaptable immunogenicity, and specific organ targeting. NeoVac's technology is applicable across various therapeutic and preventive routes of intervention, including viral and bacterial vaccines, cancer immunotherapy, and autoimmune diseases.
Funding history · 1 round · $21.7M total
1 event/round · $21.7M Total Funding: $21.7M in Private Equity
Nov 2025
Seed
$21.7M
pitchbook.com
★ Add Ventures★ Future Planet Capital★ Centre for Process Innovation
Headcount over time
27 employees (2026-09) · 1 point
Offices
Oxford, United Kingdom · HQ / main office
Q&A
- What is NeoVac's primary focus?
- NeoVac is a clinical-stage pharmaceutical company that develops next-generation lipid nanoparticle (LNP) technologies for mRNA vaccines and therapeutics.
- Where is NeoVac's headquarters located?
- NeoVac's headquarters is located in Oxford, United Kingdom.
- What is NeoVac's total funding to date?
- NeoVac has raised a total of $21,700,000 USD.
- When did NeoVac complete its Seed funding round and who were the lead investors?
- In November 2025, NeoVac completed a Seed funding round. The lead investors were Add Ventures and Future Planet Capital.
- Who is the current CEO of NeoVac?
- Jan Hendrik Egberts was appointed CEO of NeoVac in September 2025.
- What technologies does NeoVac utilize?
- NeoVac utilizes Lipid Nanoparticles (LNP) and mRNA Technology.
- What therapeutic areas does NeoVac's technology aim to address?
- NeoVac's technology is applicable across various therapeutic and preventive routes of intervention, including viral and bacterial vaccines, cancer immunotherapy, and autoimmune diseases.
Team · 5
Dan Peer
Founder · Chairperson
Adrian Hill
Founder · Chairperson of the Scientific Advisory Board
Eran Eilat
Founder · Senior Advisor and Co-Founder
Jan H. Egberts
Chief Executive Officer
Heinrich Haas
Chief Technology Officer
Sectors & technology
Primary sector
Biotechnology
Technologies
Target customers
Business model
B2BB2C
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | neovac.co.uk |
|---|
Identifiers & details
| Legal name | NEOVAC LTD. |
|---|---|
| Founded | 2021 |
| Employees (exact) | 27 |
Radar intelligence
Patents
| EPO | 14 |
|---|
Publications (Crossref)
| Works | 3 |
|---|
Web history (Wayback)
| Domain | neovac.co.uk |
|---|